Hormonal
Oral delivery of GLP-1 analogs (semaglutide, exenatide, dulaglutide) using liposomes containing tetraether lipids (TELs) and cell-penetrating peptides (CPPs) significantly increases cellular uptake in intestinal epithelial models compared to free peptides or conventional liposomes.
This research suggests a promising future where GLP-1 drugs (like Ozempic or Wegovy) could be taken orally using advanced liposome technology, potentially replacing injections. Currently, this is pre-clinical data showing high uptake in cell models, not a available product.
a highly increased uptake of all three GLP-1 analogs encapsulated into the liposomes containing TELs and CPPs in comparison to the free compound could be demonstrated on CaCo-2 cells.
Why this rating
In vitro cell culture model (CaCo-2); lacks in vivo human efficacy data in this specific paper.
Source
Liposomes Containing Tetraether Lipids and Cell‐Penetrating Peptides as Platform Technology for Oral Delivery of Peptides: A Comparative Study on GLP‐1 Analogs
Lorenz Herbster et al. · Nano Select · 2025
DOI 10.1002/nano.70010
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →